首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.
【24h】

Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

机译:白细胞介素-15增强了正常淋巴细胞中催化的蛋白酶体降解:大粒状淋巴细胞白血病的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Large granular lymphocyte (LGL) leukemia is a clonal proliferative disease of T and natural killer (NK) cells. Interleukin (IL)-15 is important for the development and progression of LGL leukemia and is a survival factor for normal NK and T memory cells. IL-15 alters expression of Bcl-2 family members, Bcl-2, Bcl-XL, Bim, Noxa, and Mcl-1; however, effects on Bid have not been shown. Using an adoptive transfer model, we show that NK cells from Bid-deficient mice survive longer than cells from wild-type control mice when transferred into IL-15-null mice. In normal human NK cells, IL-15 significantly reduces Bid accumulation. Decreases in Bid are not due to alterations in RNA accumulation but result from increased proteasomal degradation. IL-15 up-regulates the E3 ligase HDM2 and we find that HDM2 directly interacts with Bid. HDM2 suppression by short hairpin RNA increases Bid accumulation lending further support for HDM2 involvement in Bid degradation. In primary leukemic LGLs, Bid levels are low but arereversed with bortezomib treatment with subsequent increases in LGL apoptosis. Overall, these data provide a novel molecular mechanism for IL-15 control of Bid that potentially links this cytokine to leukemogenesis through targeted proteasome degradation of Bid and offers the possibility that proteasome inhibitors may aid in the treatment of LGL leukemia.
机译:大颗粒淋巴细胞(LGL)白血病是T和天然杀伤(NK)细胞的克隆增殖疾病。白细胞介素(IL)-15对于LGL白血病的开发和进展是重要的,并且是正常NK和T存储器细胞的存活因子。 IL-15改变Bcl-2家族成员,Bcl-2,Bcl-XL,BIM,NOXA和MCL-1的表达;但是,尚未显示对投标的影响。使用采用的转移模型,我们表明,当转移到IL-15-禁止小鼠时,来自出价小鼠的NK细胞从野生型对照小鼠的细胞存活。在正常的人NK细胞中,IL-15显着降低了竞标。出价的减少不是由于RNA积累的改变,而是由增加的蛋白酶体降解产生。 IL-15 up-indumates e3连接酶HDM2,我们发现HDM2直接与出价互动。通过短发夹RNA的HDM2抑制提高了BID积累贷款进一步支持HDM2参与竞争降解。在初级白血病LGLS中,出价水平低,但在硼齐佐米的治疗中,随后增加LGL细胞凋亡。总的来说,这些数据为IL-15进行了一种新的分子机制,用于通过靶向的蛋白酶体降解潜在地将该细胞因子与白血病联系起来,并提供蛋白酶体抑制剂可能有助于治疗LGL白血病的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号